BOSTON and PARIS, Sept. 27, 2021 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc., (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the ...

- BOTOX® is the First and Only FDA-Approved Neurotoxin Treatment for Both Upper and Lower Limb Spasticity - DUBLIN, Jan. 22, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global ...

BURLINGTON, Ontario, December 17, 2024--(BUSINESS WIRE)--Merz Therapeutics, a business of Merz Group and a leader in the field of neurotoxins, today announced that Health Canada approved XEOMIN ® ...

UK regulators have issued a green light for the use of Botox (botulinum type A) to treat ankle disability in patients who have suffered a stroke. UK regulators have issued a green light for the use of ...

Background OnabotulinumtoxinA has demonstrated significant benefit in adult focal spasticity. This study reviews the injection patterns (i.e., muscle distribution, dosing) of onabotulinumtoxinA for ...

In the United States, someone has a stroke every 40 seconds.[i] Though stroke death rates have declined in recent decades, it is a leading cause of serious long-term disability,[ii] taking a toll on ...

Merz Therapeutics, a business of Merz Group and a leader in the field of neurotoxins, announced that Health Canada approved Xeomin (incobotulinumtoxinA) for the treatment of post-stroke lower limb ...

The treatment was already approved for pediatric upper limb spasticity earlier this year. This new approval was based on data from a phase 3 trial evaluating the safety and efficacy of Botox in 381 ...

Spasticity is a common consequence of upper motor neuron lesions such as stroke, cerebral palsy and multiple sclerosis, characterised by a velocity-dependent increase in muscle tone and ...